BioNTech SE has announced its all-stock acquisition of CureVac, marking a significant step in its strategic expansion in the field of mRNA-based cancer immunotherapy. The transaction, approved by both companies' management and supervisory boards, aims to enhance BioNTech's research, development, manufacturing, and commercialization capabilities. By integrating CureVac's research and manufacturing site in Tübingen, BioNTech seeks to leverage complementary scientific capabilities and proprietary technologies to accelerate the development of transformative mRNA-based medicines. The acquisition is expected to close in 2025, subject to customary closing conditions and regulatory approvals.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。